RxDoctor Payments Data

Julie Lundy, MD

Family Medicine · Longview, TXNPI 1992919682

Payments from drug & device makers

$8,783in general payments, 2019–2025

Across 626 payments — averaging $14.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • GSK$897
  • Amgen$818
  • Merck$378
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$8,72699%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,783 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$448,493
Medicare patients
398
Services billed
25,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$167,648
MounjaroTirzepatide56$69,261
EliquisApixaban51$48,993
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$35,641
JardianceEmpagliflozin46$35,289
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$24,088
NuedextaDextromethorphan Hbr/Quinidine13$19,651
JanuviaSitagliptin Phosphate17$17,439
Xigduo XrDapaglifloz Propaned/Metformin13$15,228
XareltoRivaroxaban18$12,535
Repatha SureclickEvolocumab14$11,400
SymbicortBudesonide/Formoterol Fumarate14$8,808
Tresiba Flextouch U-100Insulin Degludec16$8,706
Dexlansoprazole DrDexlansoprazole27$8,623
BelsomraSuvorexant14$6,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,172$167,64894 claims
Lilly USA, LLCMounjaro$369$69,26156 claims
PfizerEliquis, Premarin$1,016$53,23867 claims
GSKTrelegy Ellipta$897$35,64132 claims
Boehringer IngelheimJardiance$173$35,28946 claims
MerckJanuvia, Belsomra$378$23,60531 claims
Avanir Pharmaceuticals, Inc.Nuedexta$14$19,65113 claims
Johnson & JohnsonXarelto$250$12,53518 claims
AstraZenecaSymbicort$256$8,80814 claims
AbbVieSynthroid$1,285$4,50863 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →